2023-08-15 18:26:32 ET
More on BioXcel Therapeutics
- BioXcel's Struggles: From FDA Issues To Financial Instability
- BioXcel Therapeutics, Inc. ( BTAI ) Q2 2023 Earnings Call Transcript
- BioXcel: Data Integrity Concerns Muddy Regulatory Outlook (Rating Downgrade)
- BioXcel Therapeutics: Serenity III Part 1 Didn't Meet Primary Endpoints, Part 2 Will
- BioXcel falls on plans for business reorganization
- Biggest stock movers today: BlackBerry, FREYR Battery, BioXcel Therapeutics, and more
- BioXcel sheds 58% as data integrity issues cloud Alzheimer’s trial win
- BioXcel trades lower after mixed results for lower dose Igalmi for bipolar agitation
- Seeking Alpha’s Quant Rating on BioXcel Therapeutics
- Earnings data for BioXcel Therapeutics
For further details see:
Mizuho cuts BioXcel to neutral, cites reduced expectations for lead drug